February 2023

Contents

Editorial

• HTB January/February 2023 (1 February 2023)

Conference reports

• 30th Conference on Retroviruses and Opportunistic Infection (CROI 2023)

• Glasgow HIV Congress (2022)

• Glasgow 2022: pipeline studies with bNAbs N6LS and maturation inhibitor GSK254

• Glasgow 2022: doravirine updates

• Glasgow 2022: long-acting cabotegravir/rilpivirine: adverse events, implementation and PROMs

• Glasgow 2022: community statement on HIV and ageing

Antiretrovirals

• Lenacapavir approved in the US for multidrug resistant HIV

• More evidence for recycling tenofovir in second-line ART with dolutegravir: 72-week results from ARTIST study

• Low level viral load on effective ART is linked to clonal expansion of reservoir: not affected by modifying ART

• Integrase inhibitors associated with higher increases in CD4:CD8 ratio than PI- or NNRTI-based ART

Pregnancy

• Zero transmission in France for mothers on ART from conception with undetectable viral load at delivery

mpox

• Update on mpox: sleeping or hiding?

Coinfections and complications

• Superinfection detected in up to 7% of people in Swiss HIV Cohort Study

• Potential to use BOTOX for erectile dysfunction

• Cases of Kaposi’s Sarcoma (KS) in people on effective ART

• Shorter course of less-intensive treatment for visceral leishmaniasis

HIV prevention and transmission

• 56 Dean Street as a nurse-led PrEP clinic: >20,000 clients in 2021

Vaccines and microbicides

• Phase 3 Mosaico HIV vaccine efficacy trial stopped early due to lack of benefit

On the web

• 24th International Workshop on Long-term Complication of HIV and SARS-CoV-2

PDFs

• HTB: no. 1/2 (January/February 2023) PDF download